The Therapeutic Goods Administration (TGA) has made an interim decision to create new Schedule 8 entries for cannabis (which is currently Schedule 9), botanically derived extracts and Tetrahydrocannabinols (THC) where they are botanically derived from cannabis. They say this has been done to enable appropriate access to medicinal cannabis products and to reflect the low risk of dependence when compared to opioids.
